The landscape of diabetes management is transforming, as continuous glucose monitoring (CGM) devices expand beyond Type 1 diabetes and into a rapidly growing Type 2 market. Changes to regulatory approvals and insurance coverage driven by improved patient outcomes have opened the door for non-insulin-dependent Type 2 patients to access CGM. Device manufacturers now face a new frontier: designing CGM hardware that meets the unique needs of an increasingly diverse patient population. For CGMs to realize their full potential in Type 2 diabetes management, it’s critical to rethink hardware design to cater to this population’s distinct requirements, improving usability, flexibility, and the quality of care.

In this article, Stuart Long explores the critical connection between stress and heart health, and discuss how AI-powered remote cardiac monitoring can help high-risk individuals avoid preventable cardiac events, especially during the holiday season.

Avania will evolve, invest, and pivot with the industry so it can achieve its mission of partnering with MedTech sponsors to bring life-changing technology to market, resulting in improved healthcare outcomes.